This study examines the cooperative effects of a human estrogen receptor-␣ (ER␣) isoform on estrogen (E 2 )-mediated gene activation in U2-OS osteosarcoma cells. ⌬5ER␣, an alternatively spliced ER␣ variant lacking exon 5, is coexpressed with normal ER␣ in several E 2 -responsive neoplastic tissues. However, the potential interactions of ⌬5ER␣ with normal ER␣ have not been functionally characterized. ⌬5ER␣ encodes the hormone-independent trans-activating function (AF-1), as well as the constitutive receptor dimerization and DNAbinding domains. It is generated by an alternate splice event that omits exon 5 and alters the reading frame of the resulting mRNA. The ⌬5ER␣ protein is prematurely truncated and lacks the majority of the hormone-binding and activating function-2 (AF-2) domains. When ⌬5ER␣ mammalian expression vector was transfected alone in human ER␣/ER␤-negative osteosarcoma U2-OS cells, it had no effect on either basal or E 2 -mediated EREtk81Luc reporter transcriptional activity, while transfected cells expressing control normal ER␣ increased EREtk81Luc activity up to 20-fold in response to 10 nM E 2 . However, when ⌬5ER␣ was cotransfected with normal ER␣, both basal and E 2 -stimulated EREtk81Luc reporter activation were increased approximately 500% over levels observed when cells were transfected with ER␣ alone. Similar effects of ⌬5ER␣ and normal ER␣ coexpression were observed using an E 2 -responsive human C3 promoter/luciferase reporter construct. The effects of ⌬5ER␣ on normal ER␣ were further assessed in U2 
INTRODUCTION
Estrogen (E 2 ) has long been known to promote the growth of certain human neoplasms, notably tumors of the breast, endometrium, and pituitary. It also modulates the development and function of normal tissues, such as bone, as well as the cardiovascular and central nervous system (1, 2) . The mitogenic and regulatory effects of E 2 are mediated through its two nuclear receptors, estrogen receptor-␣ and -␤ (ER␣ and ER␤), ligand-activated transcription factors that are members of the steroid receptor superfamily (3, 4) . The genomic structure of the ER␣ gene reveals strong homology to viral v-erbA, suggesting that ER␣ is a cellular homolog of this oncogene (3) . ER␣ is encoded by eight exons within a genomic locus of greater than 140 kb (5) . It has been well documented that ER␣ isoform variants generated by alternative splicing of ER␣ heteronuclear RNA are coexpressed in a number of human normal and neoplastic tissues (6) (7) (8) (9) (10) (11) (12) (13) . Thus, ER␣ gene expression and alternative splicing have been postulated to create a heterogeneous population of ER␣ isoforms with differential transcriptional activity, which may help to potentiate the diverse action of E 2 through a single gene.
The ER␣ protein is composed of several structural domains, each of which has a unique function in ligand binding, gene promoter activation, and association with other members of the general transcriptional apparatus (14) . The A/B domain has a ligand-independent gene activation function (AF-1) and is encoded by exon 1. It has been shown to be important for stimulating transcription from certain E 2 -responsive genes such as pS2 (14) , c-fos (15) , and C3 (16) . In addition, it is also critical for growth factor interactions with ER␣-signaling pathways both in yeast and mammalian cells (17) . However, because the A/B domain cannot bind DNA directly, it has been hypothesized to activate target genes by associating with components of the core transcriptional machinery, such as TFIID and other coactivators/repressors (18) . The ER␣ DNAbinding domain (DBD) lies within the C region and is encoded by exons 2 and 3. The DBD is composed of two type II zinc (Zn) finger motifs that have been shown by structure/function studies to be directly responsible for DNA promoter sequence recognition (19) . The D region (or variable hinge region) is thought to allow the ER␣ to alter conformation and is encoded by exon 4. This ER␣ domain may potentiate much of the allosteric regulation of the receptor after ligand binding (14) . It also contains a constitutive nuclear localization signal as well as sequences required for dimerization of the ER␣. Finally, the COOH-terminal E region is encoded by exons 5-8. It is functionally complex and is the most characterized domain in terms of structure and function (20) (21) (22) . The E region contains protein sequences important for 1) heat-shock protein association in the cytoplasm, 2) nuclear localization, 3) liganddependent receptor dimerization and the AF-2 gene activation function, and 4) E 2 and antiestrogen ligand binding.
This study focuses on the cooperative effects of human ⌬5ER␣. This variant encodes the A/B domain as well as the C and D domains critical for binding estrogen-response elements (EREs), receptor dimerization, and nuclear localization, but lacks the hormone-binding domain. It is generated by an exon 5 splice deletion, and the subsequent fusion of exons 4 and 6 results in an immediate frame shift, a short novel carboxyl terminus (GTRQNV), and termination codon. The exon-5 ER␣ spliced variant ⌬5ER␣ has been shown by others to have approximately 10-15% constitutive transcriptional activity of normal ER␣ when expressed alone in yeast (23) . However, little is known as to their potential cooperative effects when coexpressed with normal ER␣. We and others have shown that in E 2 -sensitive human tissues, ⌬5ER␣ variant isoform was typically found to be coexpressed with normal receptor. Both tamoxifen-resistant and primary breast tumors express ⌬5ER␣ along with normal ER␣. ⌬5ER␣ expression was elevated in ER␣ϩ tumors that were tamoxifen-resistant and in ER␣Ϫ tumors that expressed the E 2 -responsive markers, PgR (progesterone receptor) and pS2 (24) . In pituitary tumors, ⌬5ER␣ was found to be tumor specific and coexpressed with normal ER␣ only in prolactinomas and gonadotroph tumors, but not in normal pituitary or other pituitary tumor phenotypes (13) . Therefore, we hypothesized that ⌬5ER␣ may interact with normal ER␣ and may play a role in tumor pathogenesis
The present study examined the hypothesis that the ⌬5ER␣ tumor-specific splice variant is capable of regulating E 2 -responsive genes, which, in turn, control cellular phenotype and growth. These experiments investigated 1) the transcriptional effects of coexpression of ⌬5ER␣ and normal ER␣ on E 2 -responsive gene promoter/reporter constructs, 2) the ability of ⌬5ER␣ and normal ER␣ to stably bind ERE complexes in electrophoretic mobility shift/supershift assays (EMSAs) using nuclear extracts from stable cell lines harboring either normal ER␣ or ⌬5ER␣, and 3) the effects of ⌬5ER␣ on cellular proliferation rates in stably transfected human U2-OS osteosarcoma cell lines.
RESULTS

Cloning and Characterization of Human ER␣ and ⌬5ER␣
Normal ER␣ and ⌬5ER␣ full-length cDNA were cloned by RT-PCR from pooled human gonadotroph and lactotroph tumor mRNA. These pituitary tumor subtypes have been previously shown to express the ⌬5ER␣ variant in a tumor-specific manner along with fulllength ER␣ (13) . Figure 1A shows the exon/intron structure and functional domains of normal ER␣ as well as ⌬5ER␣. ⌬5ER␣ is created by an RNA splice omission of exon 5, causing a fusion of exons 4 and 6, which acts to shift the open-reading frame and creates a truncated carboxy terminus. As a result of this altered splice event, ⌬5ER␣ lacks almost the entire ligand-binding and AF-2 region and cannot bind E 2 . Figure 1B shows the expected in vitro translation protein products from normal human ER␣-and ⌬5ER␣-cloned cDNAs. [ 35 S]methionine-labeled protein products from ER␣ and ⌬5ER␣ cDNAs migrated at the expected sizes of 67 and 41 kDa, respectively.
Cloned normal human ER␣ and ⌬5ER␣ cDNAs were ligated into the pBKCMV expression plasmids to study their action in mammalian cells. U2-OS cells were stably transfected with either normal ER␣ or ⌬5ER␣ to generate cell lines which harbor and constitutively express each ER␣ isoform. Geneticin (G418)-resistant clonal U2-OS cell lines were isolated and human ER␣ isoform expression was examined by immunocytochemistry using a human ER␣-specific antibody which recognized an epitope within the A/B domain (residues 22-43) of both ⌬5ER␣ and normal ER␣. Immunocytochemical data for these stable cell lines are shown in Fig. 2 . Figure 2A shows negative control parental U2-OS cells, which, based on RT-PCR analyses, do not express any form of ER␣ or ER␤. No staining could be seen in these cells with a specific human ER␣-1 antibody directed against the amino terminus of ER␣, while control in ER␣-positive MCF-7 breast cancer cells exhibited demarcated nuclear staining (data not shown). Figure 2 , B and C, shows immunocytochemical localization of ⌬5ER␣ and ER␣, respectively, within the nuclear/perinuclear compartment. The pBKCMV-driven expression of each ER␣ isoform appeared to be at equivalent levels in the [ U2-OS cells are unresponsive to E 2 levels as high as 0.1 M, with no significant increases in ERE-driven luciferase activity above control wells. However, when transiently transfected with pBKCMV/ER␣, U2-OS cells exhibited significant (P Ͻ 0.05) up-regulation of EREtk81Luc activity at E 2 doses as low as 1 nM. Normal ER␣ activation of the reporter construct was found to be E 2 dose-dependent, ranging from 9-to 15-fold activation with administration of 10 Ϫ9 to 10 Ϫ7 M E 2 , respectively. No activation was seen at any E 2 dose in cells that were transiently transfected with empty pBKCMV vector. These data confirm that U2-OS cells lack endogenous ER␣ or ER␤ with a concomitant inability to activate ERE transcription. Moreover, the nonresponsive phenotype can be rescued by transfection of pBKCMV/ER␣, which enables U2-OS cells to up-regulate E 2 -dependent gene transcription in response to physiological levels of exogenous E 2 .
To examine the effects of normal ER␣ and ⌬5ER␣ on E 2 -responsive gene transcription, U2-OS cells were transiently transfected with ER␣ and/or ⌬5ER␣ along with EREtk81Luc, followed by treatment with E 2 . The results of these cotransfection studies are shown in Fig. 4A . ⌬5ER␣ had no constitutive or E 2 -stimulated effects on EREtk81Luc transcription when expressed alone in U2-OS cells. However, coexpression of ⌬5ER␣ with normal ER␣ resulted in significant upregulation of both basal (P Ͻ 0.01) and E 2 -stimulated (P Ͻ 0.001) EREtk81Luc activity 4-and 33-fold, respectively, over basal levels in the control osteosarcoma (OS) cells, or approximately 5-fold compared with cells transfected with ER␣ alone. Transfection of 2 g of ER␣ increased basal and E 2 -stimulated luciferase reporter activity approximately 2-fold over levels seen with transfections using 1 g of ER␣. The dosedependent effect of ⌬5ER␣ on the regulation of EREtk81luc gene transcription was also examined in stably transfected [ER␣ϩ]OS cells (Fig. 4B ). Coexpression of ⌬5ER␣ with normal ER␣ significantly (P Ͻ 0.001) increased E 2 -mediated trans-activation of the classic ERE promoter in a dose-dependent manner, up to 90-fold with 3 g ⌬5ER␣ compared with [ER␣ϩ]OS cells transfected with empty pBKCMV vector. Basal levels of EREtk81luc activity also significantly increased (P Ͻ 0.001) in a dose-dependent manner up to 314% of baseline.
To determine whether coexpression of ⌬5ER␣ with normal ER␣ enhances OS cells sensitivity to lower E 2 dose administration, E 2 dose-response curves were conducted in [ER␣ϩ]OS cells that were cotransfected with either empty pBKCMV or cytomegalovirus (CMV)/ ⌬5ER␣ along with the EREtk81Luc reporter. Cells were then treated with increasing [10 Ϫ13 M to 10
E 2 doses for 24 h, and EREtk81Luc activity was subsequently assayed. Figure 5 shows an E 2 doseresponse curve in [ER␣ϩ]OS cells. Cells that coexpressed ⌬5ER␣ were 100-fold more sensitive to E 2 administration than OS cells expressing normal ER␣ alone. Moreover, the magnitude of the transcriptional response was on average 550% at higher E 2 doses [10 Ϫ10 M to 10
We repeated and confirmed our cotransfection studies using an E 2 -responsive human complement 3 promoter/luciferase reporter construct, C3T1Luc. The C3 promoter contains three E 2 -responsive regions, one of which resembles the consensus ERE sequence while the other two do not show significant homology to known EREs and act as weak EREs on heterologous promoters. However, in the context of the C3 promoter, these three EREs act synergistically to create a strong ERE enhancer (16) . The results of this experiment are shown in Fig. 6A . The C3T1luc reporter exhibited an identical pattern of activation as the heterologous EREtk81luc reporter in U2-OS cells. Basal levels of C3T1luc activity in wells cotransfected with both ER␣ and ⌬5ER␣ were enhanced by 5.5-fold over those seen in wells transfected with either ER␣ or ⌬5ER␣ alone. E2-stimulated C3T1luc activity was increased 33-fold over the basal levels and 8.7-fold over E2-treated cells transfected with ER␣ alone. In contrast, when a c-fosLuc reporter containing imperfect ERE sequences was used, both ER␣ and ⌬5ER␣ showed very little effect on c-fos transcription activity (Fig. 6B) , suggesting that the classic palindromic ERE sequences are necessary for the cooperative transcriptional effect of ER␣ and ⌬5ER␣.
Electrophoretic Mobility Shift/Supershift Assay (EMSA) Studies with Nuclear Extracts from Normal ER␣ and ⌬5ER␣ U2-OS Stable Cell Lines
To further characterize the DNA-protein interaction between classic ERE sequences and normal ER␣ and/or its ⌬5ER␣ protein variant, gel-shift assays were performed on nuclear extracts from normal ER␣ and OS cells were transiently cotransfected with 1 g of EREtk81Luc reporter vector, with or without the indicated amount of ER␣ and/or ⌬5ER␣ expression vectors, followed by 10 nM E 2 in treatment wells for 24 h. Luciferase activity was determined, and representative data shown are the mean Ϯ SEM, n ϭ 3. ***, P Ͻ 0.001 vs. control wells; *, P Ͻ 0.05 vs. basal levels with 2 g ER␣. B, ⌬5ER␣ dose response: Modulation of normal ER␣ transactivation on ERE promoter.
[ER␣ϩ]OS cells were transiently transfected with 1 g EREtk81Luc and varying amounts of ⌬5ER␣, followed by 10 nM E 2 in treatment wells for 24 h. pBKCMV vector without insert was used to keep constant stoichiometric levels of CMV promoter in each transfected well (total CMV vector DNA ϭ 3 g/well). Data are the mean Ϯ SEM, n ϭ 3. All basal and E 2 -stimulated levels were significantly elevated (P Ͻ 0.001) over ⌬5ER␣-negative basal values as measured by Student's t-test. Cells stably expressing CMV/ER␣ were transiently transfected with 1 g/well CMV/⌬5ER␣ and EREtk81Luc. Wells were then treated with 10 nM E 2 for 24 h and assayed for luciferase activity. Values are the mean Ϯ SEM, n ϭ 3. *, P Ͻ 0.001 compared with minus ⌬5ER␣ control by Student's t-test.
⌬5ER␣ stable cell lines, and results from these EMSAs are shown in Fig. 7 . There was a faint, but detectable, band shift of labeled ERE oligonucleotide in nuclear extracts prepared from parental ER␣-negative U2-OS cells (lanes 1 and 2). As expected, nuclear extracts derived from ER␣-stably transfected cells showed a marked increase in protein-ERE complexes with E 2 treatment (lanes 3 and 4). Conversely, ⌬5ER␣ nuclear extracts were capable of binding ERE oligonucleotide, independent of E 2 (lanes 5 and 6). In addition, in ER␣/ ⌬5ER␣ mixed extracts, this shifting pattern was increased in intensity in the presence of E2 (lanes 7 and 8). The specificity of the gel-shift was demonstrated by competition assays with excess, unlabeled ERE DNA (Fig. 7, lanes 9-14) .
Supershift experiments with antibodies specific to the amino and carboxy termini of normal ER␣ and ⌬5ER␣ were carried out to determine whether the observed EMSA patterns were due to direct interactions of normal and ⌬5ER␣ variant with ERE complexes. Figure 8 shows the results of these experiments with nuclear extract from each stable U2-OS cell line. There was no detectable supershift with either antibody in parental OS extracts, while both antibodies supershifted ERE DNA in the normal ER␣ extracts. As expected, the amino terminus antibody supershifted ERE in the ⌬5ER␣ extracts. However, the carboxy-terminus antibody, which recognizes an epitope in the hormone-binding domain distal to the ⌬5ER␣ premature termination codon, failed to supershift ⌬5ER␣/ERE complexes. Finally, normal ER␣/⌬5ER␣ mixed nuclear extracts, as expected, displayed supershifted patterns of ER␣/ERE complexes with both antibodies.
Proliferation Studies Utilizing Stable U-2 OS Cells Expressing ER␣ and ⌬5ER␣ Variant
To assess the potential growth effects of ⌬5ER␣ variant, we conducted growth studies of each stable cell line. Stable transfectant U2-OS cell clones were screened for the expression of ER␣ and ⌬5ER␣ mRNA by Northern blot analysis (data not shown) and immunocytochemistry (ICC) using a monoclonal antibody against the A/B domain common to each ER␣ receptor studied (as shown in Fig. 2 ). 
DISCUSSION
This study examines the cooperative effects of the human ⌬5ER␣ isoform with normal ER␣ on estrogen (E 2 )-mediated gene activation in U2-OS osteosarcoma Cells were plated at a density of 1 ϫ 10 4 cells per well (day 0) and were grown in phenol red-free DMEM containing 5% charcoal-stripped FCS. Cell number was determined by Coulter cell counting, and representative data shown are the mean Ϯ SEM of triplicate wells. *, Statistically significant differences in the growth curve by two-way ANOVA in cell growth as compared with parental U2-OS cells. ⌬5ER␣ Enhances E 2 -stimulated Gene Transcriptioncells. It demonstrates that the human ⌬5ER␣ isoform can markedly enhance the transcriptional effects of normal ER␣ on E2-responsive genes in this human cell line. ⌬5ER␣, an alternatively spliced ER␣ variant lacking exon 5, is coexpressed with normal ER␣ in several E 2 -responsive neoplastic tissues, including primary pituitary (13), endometrial (25) , and breast tumors (26, 27) . These studies provide direct, functional evidence demonstrating that ⌬5ER␣ can markedly up-regulate both basal and E 2 -stimulated classical ERE promoter gene activation when coexpressed with normal ER␣ in vitro. It also details experiments describing the subcellular distribution, DNA-binding ability, and proliferative potential of ⌬5ER␣ variant in the human U2-OS cell line.
As predicted by its structure, the ⌬5ER␣ variant has similarities to normal ER␣ as well as important differences. It encodes the A/B domains as well as the C and D domains critical for DNA binding and constitutive nuclear localization, respectively. EMSA experiments demonstrate that nuclear extracts from cells stably expressing ⌬5ER␣ can bind ERE sequences in the presence and absence of E 2 . Immunocytochemistry utilizing stable cell lines harboring the ⌬5ER␣ expression vector confirm that the truncated protein is expressed and at least partially compartmentalized in the cell nucleus. However, due to an alternate splice event that omits exon 5 and alters the reading frame of the resulting mRNA, the ⌬5ER␣ protein is prematurely truncated and lacks the majority of the hormone-binding and activating function-2 (AF-2) domains. Coupled in vitro transcription/translation of ⌬5ER␣ cDNA demonstrates that the cloned isoform encodes the expected 41-kDa protein product lacking the hormone binding and AF-2 domains. Transient transfection of ⌬5ER␣ demonstrates that it is unable to trans-activate E 2 -responsive reporter vectors in the presence of E 2 .
Previous studies have conclusively demonstrated that ⌬5ER␣ has minimal constitutive activity when expressed either in yeast or mammalian cells (6, 7, 23, 28) . Experiments in which ⌬5ER␣ was transfected with either the EREtk81Luc or C3Luc reporter constructs confirmed these results. When ⌬5ER␣ cDNA was transfected alone in human ER␣/ER␤-negative osteosarcoma U2-OS cells, it had no effect on either basal or E 2 -mediated EREtk81Luc or C3T1luc reporter transcriptional activity. However, this cell line clearly contains the basic transcriptional apparatus to up-regulate E 2 -stimulated gene activity, because transfected cells expressing control normal ER␣ increased EREtk81Luc activity up to 20-fold in response to 10 nM E 2 . These findings with normal ER␣ are in agreement with other studies that examine normal ER␣ activation of E 2 -responsive gene transcription in various OS cell lines (29) (30) (31) (32) (33) . Our data also confirm previous studies that show that the ⌬5ER␣ isoform has minimal activity when expressed alone. However, when ⌬5ER␣ was cotransfected with normal ER␣, both basal and E 2 -stimulated EREtk81Luc reporter activation were increased approximately 500% over levels observed when cells were transfected with ER␣ alone. Similar effects of ⌬5ER␣ and normal ER␣ coexpression were observed using an E 2 -responsive human C3 promoter/ luciferase reporter construct.
Because these data were obtained using transient transfection of U2-OS cells, we chose to extend and confirm these observations in stable cell lines expressing normal ER␣. This approach allowed us to quantitatively assess the impact of ⌬5ER␣ coexpression on normal ER␣ transactivation. Transfection of increasing amounts of ⌬5ER␣ expression vector into [ER␣ϩ]OS cells resulted in potentiation of both basal and E 2 -stimulated ERELuc activity in a synergistic, dosedependent manner. Collectively, these transient and stable transfection studies confirm what the structure of ⌬5ER␣ predicts: When expressed alone in an ER␣-negative cell, ⌬5ER␣ is unable to bind E 2 and fails to up-regulate either EREtk81luc or C3T1luc gene activity either in the presence or absence of E 2 . However, the unexpected result in this study is that ⌬5ER␣ can act as a dominant positive receptor isoform and facilitate both basal and E 2 -stimulated ERE-mediated transcription of normal ER␣ when coexpressed in U2-OS cells.
The mechanism underlying the observed constitutive and E 2 -stimulated transcriptional activation of the classic ERE promoter by ⌬5ER␣ and normal ER␣ may be due to formation a ⌬5ER␣/ER␣ heterodimer capable of binding ERE promoter sequences and activating transcription independent of E 2 . Several studies utilizing site-specific mutagenesis of ER␣ in both yeast expression systems and MCF-7 cells have led to the general hypothesis that ER␣ activation of gene transcription is facilitated by an interaction between AF-1 in the A/B domain and AF-2 in E domain (34) (35) (36) . However, both AF-1 and AF-2 can also activate transcription independently, and each can bind the basal transcription components of the preinitiation complex directly, notably TFIIB and TFIID, in a ligand-independent manner in vitro (37, 38) . In addition, ⌬5ER␣ encodes a recently described third activation domain, AF2a, located between residues 282 and 351 of the D region (39) . Data from electromobility shift/supershift assays using nuclear extracts of U2-OS cells stably transfected with ER␣ and ⌬5ER␣ confirmed the constitutive binding of ⌬5ER␣ protein to ERE-containing complexes in the presence and absence of E 2 . Parallel with transcriptional studies, EMSA also showed the expected increase in ER␣-or ER␣/⌬5ER␣-ERE complexes with E 2 treatment. The observed increase in the receptor-ERE bound complex with E 2 treatment has been described as a result of the formation of ER␣ DBD-ERE complexes with greater stability (19, 40) . These findings suggest the possibility that altered structure of ⌬5ER␣ truncated receptor may promote enhanced binding to ERE promoters even in the absence of E 2 . Taken together, the results from functional transfection studies on the classic ERE transcription and gel shift assays of direct DNA-protein interactions in vitro are consistent with both constitu-tive and cooperative transcriptional activation of the classic ERE promoter by the coexpressed ⌬5ER␣ and normal ER␣.
In this study we found that human osteosarcoma cell lines stably transfected with a ⌬5ER␣ expression vector exhibit E 2 -independent increases in cellular growth rates. Proliferation rates of stable U2-OS cell lines expressing ⌬5ER␣ were significantly increased (P Ͻ 0.05), with cell-doubling times reduced from 35 h in control parental U2-OS cells to 28 h in [⌬5ER␣]OS cells. Tamoxifen or E 2 treatment had no significant effect on cellular proliferation rates in any of the U2-OS stable cell lines studied. This is not unexpected in ⌬5ER␣ stable lines because of a lack of ligand-binding domain in the truncated receptor. In contrast to our proliferation data in U2-OS cells, ⌬5ER␣ has been shown to have little effect on MCF-7 breast cancer cell growth in response to E 2 or tamoxifen (41). These differences in ⌬5ER␣ growth effects in MCF-7 cells may be confounded by endogenous production of ⌬5ER␣ as well as a number of other ER variants in that cell line (8) . Alternatively, these data may represent cell-specific mechanisms of ⌬5ER␣ action on cellular proliferation in human osteosarcoma cells.
In contrast to growth effects seen with ⌬5ER␣, U2-OS cells stably transfected with normal ER␣ showed insignificant alterations in proliferative potential when compared with parental U2-OS cells and were not affected by treatment with either E 2 or tamoxifen. These findings are consistent with several characterized human osteosarcoma cell lines which either fail to respond or inhibit growth in the presence of E 2 in vitro. These proliferative responses may depend, in part, on exogenous ER␣ expression levels. For example, in the HTB 96 human OS cell line, E 2 caused a growth-inhibitory response in lines that were stably transfected with ER␣, when compared with a parental HTB 96 OS cell line (32) . Human SaOS-2 cell lines stably transfected with ER␣ also exhibit growth inhibition when treated with E 2 (29) . However, similar growth studies with HOS TE85 human osteoblastic cells exhibited no proliferative response to exogenous E 2 (30) . Thus, although the proliferative effects of E 2 in other human cell lines derived from E 2 -sensitive tissue (i.e. uterus and breast) are well-characterized, the data in osteoblast-like osteosarcoma cell lines suggest E 2 effects on proliferative potential are limited in this in vitro cellular system.
It is unclear how the truncated ⌬5ER␣ lacking the ligand-binding domain can enhance cellular proliferation in stable U2-OS cells. Several studies have demonstrated that the A/B domain containing AF-1 of the ER␣ is important for peptide growth factor interaction, independent of E 2 (18, 37) . Moreover, a mutagenesisgenerated ER␣ isoform lacking much of the hormonebinding domain E has also been shown to activate c-fos promoter independent of E 2 administration in HeLa cells (42) . Therefore, the naturally occurring ⌬5ER␣, which encodes only the A/B (AF-1) and DBD domains, might function to up-regulate growth factorinduced proliferative responses. One potential hypothesis is that this isoform is a potent target for peptide growth factor kinase-signaling pathways that influence its interactions with other coregulatory proteins. This may result in enhanced cellular growth in the absence of stimulation of ERE-dependent gene activation, and an E 2 -independent growth phenotype.
Studies examining potential interactions of structurally altered ER␣ isoforms may have important implications for the well described ER␣ isoform coexpression observed in human E 2 -sensitive neoplastic tissues. If ER␣ isoform expression plays a role in growth regulation of E 2 -sensitive tumor cells, dysregulation of mRNA-splicing mechanisms that give rise to these variants in neoplastic cells may be selective during tumor progression to a more aggressive phenotype. These data are consistent with interactive effects of normal ER␣ and ⌬5ER␣ on transcription from classic ERE gene promoters and suggest that coexpression of these ER␣ isoforms may alter cellular phenotype, growth, and E 2 -mediated gene activation. Given the observed effects of ⌬5ER␣ on normal ER␣ function, we hypothesize that this ⌬5ER␣ variant may have pathophysiological consequences in these tissues. Based on these data, we hypothesize that ⌬5ER␣ potentiates E 2 and normal ER␣ actions on cellular growth, differentiation, and/or neoplastic progression in human E 2 -responsive tissues expressing both ⌬5ER␣ and normal ER␣.
MATERIALS AND METHODS
Plasmid Constructs
Full-length normal human ER␣ and its variant ⌬5ER␣ were cloned from human pituitary tumor cDNA into the eukaryotic pBK-CMV expression vector (Stratagene, La Jolla, CA). Briefly, pooled pituitary first-strand cDNA obtained from human lactotroph and gonadotroph tumors by reverse transcription served as template for PCR amplification using a high-fidelity Pfu DNA polymerase (Stratagene) as previously described (13) . Primer pairs SpeI-ER␣ (5Ј-gga cta gtc cat gac cat gac cct CCA-3Ј) and ER␣4L (5Ј-ttc gcc cag ttg atc atg tg-3Ј) were used to amplify the N-terminal portion of ER␣ (nucleotides 231-1298, GenBank Accession no. X03635) while ER␣4U (5Ј-gcc ccc cat act cta ttc-3Ј) and ER␣-ClaI (5Ј-gga tcg atg cag cag gga tta tct ga-3Ј) were used to amplify the C-terminal part of ER␣ (nucleotides 1201-2063). PCR products of the appropriate sizes for normal and variant ER␣ fragments were purified from 1% agarose gel using GlasPac/GS purification kit (National Scientific, San Rafael, CA). The N-terminal portion of ER␣ fragment was digested with SpeI and HindIII while the C-terminal portion of ER␣ and ⌬5ER␣ fragments were digested with HindIII and ClaI before cloning into pBKCMV plasmid vector. Expression plasmids containing the complete protein-coding region of ER␣ or ⌬5ER␣ were constructed by ligating the common N-terminal portion of ER␣ to the isoform-specific C-terminal portion via an overlapping unique HindIII site. Positive clones were identified and confirmed by dideoxy sequencing using primers covering the entire translated region of ER␣. Reporter plasmid EREtk81Luc contains two copies of consensus ERE palindromic sequence (aggtcacagtgacct) upstream of the minimal thymidine kinase (tk) promoter in pA3Luc (courtesy of R. Pestell, Albert Einstein college of Medicine, Bronx, NY). C3T1Luc of the human C3 promoter (Ϫ1030 to ϩ58) contains one copy of consensus ERE palindromic sequences and two non-ERE E 2 response regions (courtesy of D. P. McDonnell, Duke University Medical School, Durham, NC). The human c-fosLuc reporter contains Ϫ2000 bp upstream of the transcriptional start site to 42 bp of human c-fos promoter in pGLBasic (courtesy of C. Chen, University of Queensland, Queensland, Australia).
In Vitro Translation of ER␣ and ⌬5ER␣ Variant
pBKCMV-ER␣ or -⌬5ER␣ and the control pBKCMV (1 g) were used as DNA templates in coupled reticulocyte lysatetranscription/translation reactions in the presence of T3 RNA polymerase, amino acid mixture minus methionine, and [ 35 S]methionine in a final volume of 25 l according to the manufacturer protocols (Promega, Madison, WI). The synthesized protein products were analyzed by fractionation on a 8.5% SDS-PAGE, and the gels were dried down and autoradiographed for 24 h.
Stable Transfection and Screening
The expression vectors pBKCMV-ER␣ and its ⌬5ER␣ variant were stably transfected in ER␣/ER␤-negative human osteosarcoma cell line U2-OS (ATCC, Rockville, MD) to generate [ER␣]OS and [⌬5ER␣]OS cell lines. One ϫ 10 6 OS cells were washed with phenol red-free reduced serum OptiMEM and incubated with the mixture of 30 l lipofectamine (GIBCO BRL, Grand Island, NY) and 10 g of pBKCMV-ER␣ or its ⌬5ER␣ variant expression plasmid at 37 C for 24 h. Medium was replaced with serum-free phenol red-free DMEM and incubated for an additional 48 h. Cells were subcultured in a series of cell-plating density ranging from 5,000-50,000 cells per 10-cm culture dish, in phenol red-free DMEM containing 5% charcoal-treated FCS and geneticin G418 (GIBCO BRL) at 500 g/ml for selection. Media were then changed every 4-5 days. In 3 weeks, visible colony foci were isolated and propagated in medium containing G418.
Immunocytochemistry
Parental U-2 OS cells and stably transfected [ER␣]OS and
[⌬5ER␣] OS cells were grown on four-chamber cell culture slides (Nunc Inc., Naperville, IL) and fixed with 2% paraformaldehyde in PBS pH 7.2, for 24-48 h at 4 C. Before immunostaining, cells were washed with PBS, pH 7.2, containing 10 mM glycine for 15 min to quench unreacted aldehyde groups and rinsed twice with PBS. Cell membranes were permeabilized by 5-min incubation at room temperature with 0.2% Triton X-100 in PBS, and cells were washed twice with PBS without detergent. Nonspecific binding sites for IgG were blocked by incubating cells for 20 min with nonimmune serum (5%). Immunostaining by avidin-biotin-peroxidase complex technique was performed according to manufacturer's instructions using Vectastatin Elite ABC kit (Vector Laboratories, Burlingame. CA). The ER␣-monoclonal mouse antibody, ER␣-1 (Babco, Richmond, CA) against the common N terminus (amino acids 22-43 of the A/B domain)) of ER␣ and ⌬5ER␣, was diluted to the optimal concentration in PBS. Cells were incubated with the primary antibody for 1 h at 37 C and were washed twice with PBS for 15 min each. The diluted biotinylated secondary antibody was applied for 30 min at room temperature, and cells were washed twice with PBS before a 30-min incubation with Vectastatin Elite ABC reagent. Slides then were incubated in 1 g/ml diaminobenzidine-0.3% H 2 O 2 for 5 min, rinsed, and counterstained with hematoxylin. Coverslips were mounted to the chamber slides with immumount (Shandon, Pittsburgh, PA). Immunoabsoption controls were performed by preabsorption of the ER␣ antibody ER1 overnight at 4 C with the excess in vitro translated normal ER␣ protein. Method controls included substitution of nonimmune serum for primary antibody, elimination of secondary antibody, or streptavidin-biotin-peroxidase complexes, and dilution of primary antibodies. All controls verified the specificity of the ER1 antibody against the N terminus of ER␣ and ⌬5ER␣.
Transient Transfection and Luciferase Assay
[ER␣-]OS and [ER␣ϩ]OS cells were plated in six-well plates at a density of 2 ϫ 10 5 cells per well and allowed to adhere overnight. One hour before transfection, cells were washed and incubated in phenol red-free reduced serum OptiMEM. A lipid transfection mixture was prepared using a 1:400 mixture of Dioleoyl-a-phosphatidylethanolamine to demethyldioctadecylammonium bromide dissolved in 100% ethanol (both lipids were purchased from Sigma Chemical Co., St. Louis, MO). The DNA-lipid mix (1:5 ratio) containing the appropriate pBKCMV/ER␣ expression plasmid along with Luciferase reporter plasmid was prepared in phenol red-free reduced serum OptiMEM (1 ml/well) for 30 min at room temperature before addition to triplicate wells containing U2-OS cells. Whenever applicable, empty pBKCMV plasmid was used for experiments using pBKCMV-ER␣ or its variant to ensure that stiochiometrically equal amounts of CMV promoter, plasmid DNA, and lipid mix were applied to each well. Rous sarcoma virus/␤-galactosidase was used to monitor the variability of transfection efficiency. After 5 h incubation at 37 C, the transfection medium was replaced with serum-free phenol red-free DMEM and incubated for an additional 24 h, in the presence or absence of the indicated amount of E 2 . Transfected cells were lysed with 300 l lysis buffer containing 1% Triton X-100, 10% glycerol, 2 mM EDTA, 2 mM dithiothreitol (DTT), and 25 mM Tris-phosphate (pH 7.8), and the cellular debris was removed by centrifugation. One hundred microliters of cell lysate were assayed for luciferase activity by measuring light emission with Luminometer (EG&G Berthold, Gaithersburg, MD) in the presence of luciferin and ATP.
EMSAs
Cell nuclear extracts were prepared from the parental U-2 OS, stable [ER␣ϩ]OS, and [⌬5ER␣]OS cells grown in the absence or presence of 10 nM E 2 using the miniextraction method with salt concentration modified for ER␣ extracts (43) . Briefly, 5 ϫ 10 6 to 1 ϫ 10 7 cells were collected, washed with ice-cold Tris-borate-saline, and pelleted by centrifugation at 1,500 ϫ g for 5 min. The pellet was resuspended in 400 l cold buffer A containing 10 mM HEPES, pH 7.9, 10 mM KCL, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, and 50 l protease inhibitor cocktail (Sigma). Cells were placed on ice for 15 min, followed by addition of 25 l 10% Nonidet NP-40, and were vortexed for 10 sec. After centrifugation for 30 sec in a microfuge, the nuclear pellet was resuspended in 50 l ice-cold buffer C (20 mM HEPES, pH 7.9, 0.1 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride) and lysed for 15 min at 4 C on a shaking platform. The nuclear extract was centrifuged for 5 min at 4 C, and the supernatant was stored at Ϫ80 C. Protein concentrations of the nuclear extracts were determined by Bradford microassay (Sigma).
Consensus and mutant ERE oligonucleotides were endlabeled with [␥ 32 P]ATP and polynucleotide kinase (50,000 cpm/ng). Mutant ERE was identical to consensus ERE oligonucleotide with the exception of an AG-to-CC substitution in the ERE consensus sequence. Labeled probe (10,000 cpm) was added to 20 l reaction mixture containing 1-2 g nuclear extract in EMSA binding buffer (20 mM HEPES, pH 7.6, 400 mM KCL, 1 mM DTT, and 20% glycerol) and 1 g poly(deoxyinosinic-deoxycytidylic)acid (Pharmacia Biotech, Piscataway, NJ). Binding reactions were allowed to pro-ceed at 25 C for 20 min. For competition studies, cold ERE was incubated with the appropriate nuclear extract before addition of labeled ERE probe. DNA-protein complexes were resolved by electrophoresis (150 V at 25 C) through a nondenaturing polyacrylamide gel containing 5% glycerol in 0.5ϫ Tris-borate-EDTA and were visualized by autoradiography.
For gel supershift analysis, 1-2 l of appropriate gel supershift antibodies were added per 20 l reaction volume subsequent to addition of 32 P-labeled probe and incubated for 30 min at 25 C. Gel supershift antibodies included two monoclonal ER␣ supershift antibodies (Babco) against the N terminus (ER␣-2, directed to amino acids 29-43 of the A/B domain) and the C terminus (ER␣-6, directed against amino acids 575-595 of the EF region). 
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